AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ: INGN), a developer of targeted molecular therapies for cancer, announced today its financial results for the quarter and six months ended June 30, 2008, and highlighted recent corporate and product developments.
